📊 GALT Key Takeaways
Is Galectin Therapeutics Inc. (GALT) a Good Investment?
Galectin Therapeutics is a pre-revenue pharmaceutical company with severe financial distress, negative stockholders' equity of -$125.3M, and massive ongoing cash burn of -$17.8M annually. The company lacks meaningful revenue generation, has only 11.5M in cash reserves against 136.4M in liabilities, and faces imminent liquidity crisis with a current ratio of 0.09x.
Galectin Therapeutics shows very weak fundamentals: it is pre-revenue, deeply unprofitable, and burning cash with no operating income support. Financial health is severely stressed, with negative stockholders' equity, a 0.09x current ratio, and liabilities far exceeding assets, which raises substantial going-concern and financing risk. While losses were roughly flat year over year and cash remains on hand, the overall quality of the business is poor until it can materially improve liquidity and establish a credible revenue base.
Why Buy Galectin Therapeutics Inc. Stock? GALT Key Strengths
- Maintains some cash reserves of $11.5M for near-term operations
- Relatively low capital expenditure requirements typical for biotech R&D stage
- Active insider trading activity (19 Form 4 filings in 90 days) suggests ongoing leadership engagement
- Net loss was roughly stable year over year, suggesting expense growth has not accelerated materially
- Cash and equivalents of $11.53M provide some near-term operating flexibility
- No capital expenditure burden keeps cash use concentrated in core operations rather than asset-heavy spending
GALT Stock Risks: Galectin Therapeutics Inc. Investment Risks
- Negative stockholders' equity of -$125.3M indicates technical insolvency
- Severe liquidity crisis with current ratio of 0.09x and minimal cash relative to liabilities
- Continuous operating losses of -$17.8M annually with zero revenue generation creates unsustainable cash burn trajectory
- Liabilities of $136.4M vastly exceed total assets of $12.9M with no clear path to profitability
- Pre-revenue stage with no demonstrated commercial viability or product revenue
- Pre-revenue profile means the company has no demonstrated commercial engine or gross profit base
- Severe balance-sheet weakness, including negative equity of $-125.30M and liabilities of $136.44M against only $12.87M of assets
- High cash burn and very weak liquidity, with $-17.83M operating cash flow and only 0.09x current and quick ratios
Key Metrics to Watch
- Cash balance depletion rate and runway months remaining
- Progress toward clinical trial endpoints and regulatory approvals
- Quarterly operating cash burn trends and cost reduction measures
- Debt restructuring negotiations or capital raise announcements
- Pipeline advancement and licensing/partnership deals to generate revenue
- Quarterly operating cash burn relative to cash balance
- Liquidity improvement, especially current ratio and any reduction in liabilities versus assets
Galectin Therapeutics Inc. (GALT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
GALT Profit Margin, ROE & Profitability Analysis
GALT vs Healthcare Sector: How Galectin Therapeutics Inc. Compares
How Galectin Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Galectin Therapeutics Inc. Stock Overvalued? GALT Valuation Analysis 2026
Based on fundamental analysis, Galectin Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Galectin Therapeutics Inc. Balance Sheet: GALT Debt, Cash & Liquidity
GALT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Galectin Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.76 indicates the company is currently unprofitable.
GALT Revenue Growth, EPS Growth & YoY Performance
Galectin Therapeutics Inc. Dividends, Buybacks & Capital Allocation
GALT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Galectin Therapeutics Inc. (CIK: 0001133416)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GALT
What is the AI rating for GALT?
Galectin Therapeutics Inc. (GALT) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GALT's key strengths?
Claude: Maintains some cash reserves of $11.5M for near-term operations. Relatively low capital expenditure requirements typical for biotech R&D stage. ChatGPT: Net loss was roughly stable year over year, suggesting expense growth has not accelerated materially. Cash and equivalents of $11.53M provide some near-term operating flexibility.
What are the risks of investing in GALT?
Claude: Negative stockholders' equity of -$125.3M indicates technical insolvency. Severe liquidity crisis with current ratio of 0.09x and minimal cash relative to liabilities. ChatGPT: Pre-revenue profile means the company has no demonstrated commercial engine or gross profit base. Severe balance-sheet weakness, including negative equity of $-125.30M and liabilities of $136.44M against only $12.87M of assets.
What is GALT's revenue and growth?
Galectin Therapeutics Inc. reported revenue of N/A.
Does GALT pay dividends?
Galectin Therapeutics Inc. does not currently pay dividends.
Where can I find GALT SEC filings?
Official SEC filings for Galectin Therapeutics Inc. (CIK: 0001133416) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GALT's EPS?
Galectin Therapeutics Inc. has a diluted EPS of $-0.40.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GALT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Galectin Therapeutics Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GALT stock overvalued or undervalued?
Valuation metrics for GALT: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GALT stock in 2026?
Our dual AI analysis gives Galectin Therapeutics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GALT's free cash flow?
Galectin Therapeutics Inc.'s operating cash flow is $-17.8M, with capital expenditures of $0.0.
How does GALT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.09 (avg: 2).